# Marco Boorsma

> Marco Boorsma is a Series A investor at Forbion Capital Partners backing Biotechnology. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners)
- Location: Naarden, The Netherlands
- Total investments: 13
- Last investment: Jan 2026
- Lead investor: 62%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/marco-boorsma/0/819/8aa

Marco Boorsma is a Series A investor at Forbion Capital Partners in Naarden focused on Biotechnology and Pharmaceutical. Marco Boorsma is based out of Amsterdam, Noord-Holland, and is the General Partner of Forbion and a Board of Director at Corsera Health. Marco previously worked at VectorY as a Board Director. Marco Boorsma attended the University of Groningen.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 62% |
| Pharmaceutical | 5 | 38% |
| Medical | 4 | 31% |
| Health Care | 4 | 31% |
| Therapeutics | 4 | 31% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 31% |
| Series B | 4 | 31% |
| Series C | 3 | 23% |
| Seed | 1 | 8% |
| Series D | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 23% |
| Canada | 2 | 15% |
| Norway | 1 | 8% |
| Denmark | 1 | 8% |
| Ireland | 1 | 8% |

7 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Corsera Health | Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing theproduction of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment. | $80M | Series A | Jan 07, 2026 |  |
| Orbis Medicines | Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | $93.5M | Series A | Jan 06, 2025 |  |
| Orbis Medicines | Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | $28.1M | Seed | Feb 29, 2024 |  |
| Calluna Pharma | Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These include novel therapeutic candidates that fulfill unmet clinical needs across a spectrum of diseases. | $81.4M | Series A | Jan 23, 2024 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M | Series C | Oct 17, 2022 |  |
| NorthSea Therapeutics | NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M | Series C | Dec 17, 2021 |  |
| Rectify Pharmaceuticals | Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas. | $100M | Series A | Oct 14, 2021 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M | Series B | Sep 08, 2020 |  |
| Milestone Pharmaceuticals | Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $80M | Series D | Oct 25, 2018 |  |
| Escalier Biosciences | Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands withoffices in Nijmegen, The Netherlands and Encinitas, California. | $19M | Series B | Mar 13, 2018 |  |

10 of 13 investments shown.

## Co-investors
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 5 deals together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 4 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 3 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 3 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 3 deals together
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 2 deals together

## About Forbion Capital Partners

VC Fund · Naarden, The Netherlands

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

5 contacts available at Forbion Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Joy Faucher | General Partner | https://shizune.co/investors/profile/joy-faucher-c13e |
| Marco Boorsma | General Partner | https://shizune.co/investors/profile/marco-boorsma |
| Nanna Lüneborg | General Partner | https://shizune.co/investors/profile/nanna-lneborg |
| Onno Stolpe | Venture Partner | https://shizune.co/investors/profile/onno-van-de-stolpe |
| Sander Slootweg | Managing Partner and co-founder | https://shizune.co/investors/profile/sander-slootweg |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Marco Boorsma invest in?

Marco Boorsma invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Marco Boorsma last invest?

The most recent investment recorded for Marco Boorsma closed in Jan 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co